INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF SCIENCES

Their core work

Institut Pasteur of Shanghai (IPS) is a joint research institute operated by the global Institut Pasteur network and the Chinese Academy of Sciences, focused on infectious disease biology in the Asia-Pacific context. Their H2020 participation shows a consistent specialization in emerging viral pathogens — contributing laboratory, clinical, and epidemiological expertise to international outbreak-response consortia. In ZIKAlliance they supported global coordination of Zika virus research, and in RECoVER they contributed to rapid SARS-CoV-2 clinical and epidemiological characterization during the early COVID-19 pandemic. As a Pasteur-affiliated institute in China, they occupy a strategically important position bridging Asian disease surveillance data with European research networks.

What they specialise in

How they've shifted over time

IPS's H2020 trajectory moves from arboviral/vector-borne disease (Zika, 2016) to pandemic coronavirus response (SARS-CoV-2, 2020), reflecting a broadening within the same core competency: rapid scientific response to novel viral emergencies. The keyword record for ZIKAlliance contains only a data artifact (a timestamp rather than descriptive terms), which limits insight into their specific Zika-era focus; the RECoVER keywords are much richer — clinical research, epidemiology and modeling, clinical biology — suggesting growing emphasis on translational and clinical dimensions over purely basic virology. The overall direction is toward pandemic preparedness infrastructure and multi-disciplinary outbreak response rather than any single pathogen class.

IPS is positioning itself as a standing node in European pandemic-preparedness networks — their successive involvement in two major global outbreak responses suggests they will continue to join large international consortia addressing the next emerging pathogen.

How they like to work

IPS participates exclusively as a consortium partner — they have never coordinated an H2020 project — which signals a role as specialized contributor rather than project driver. Despite only two projects, they have accumulated 66 distinct partners across 20 countries, reflecting involvement in large, geographically diverse global-health consortia where their Asia-Pacific location and Pasteur network affiliation make them a valued node. Working with IPS likely means engaging a specialist that brings unique regional data access and a well-established institutional pedigree, but not an organization that will handle consortium administration or coordination duties.

Despite only two projects, IPS has connected with 66 unique partners in 20 countries — an unusually broad footprint that reflects the inherently global architecture of infectious-disease emergency consortia. Their network spans Europe, Asia, and likely Africa and the Americas through the Zika and COVID-19 response alliances.

What sets them apart

IPS sits at a rare intersection: Institut Pasteur scientific lineage, Chinese Academy of Sciences institutional backing, and physical presence in Shanghai — giving it direct access to Asian pathogen surveillance data and patient cohorts that European partners cannot easily replicate. For any consortium studying zoonotic spillover, pandemic origins, or disease dynamics in Southeast Asia, IPS fills a geographic and institutional gap that no European research center can substitute. Their dual affiliation also smooths the regulatory and sample-transfer complexities that typically slow EU–China collaborative research.

Highlights from their portfolio

• RECoVER
  A rapid-response EU project launched at the onset of the COVID-19 pandemic (2020), making IPS one of the few non-European institutions embedded in Europe's emergency SARS-CoV-2 research infrastructure from the start.
• ZIKAlliance
  A global alliance mobilized during the 2015–2016 Zika emergency, demonstrating IPS's pattern of early engagement in WHO-priority outbreak responses well before SARS-CoV-2.